Vicore Pharma Holding AB (VICO)

Sell: 11.58 SEK|Buy: 11.68 SEK|Change: 0.58 (5.26%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Open

11.22 SEK

Previous close

11.02 SEK

Trade high

11.78 SEK

Volume

678,814

Year high

14.10 SEK

Year low

6.09 SEK

Dividend yield

–

Market capitalisation

2.72 bn SEK

P/E ratio

–

ISIN

SE0007577895

This share can be held in a Dealing account SIPP

Share price

Performance 15/10/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Vicore Pharma Holding AB	+ 0.18
More...

Company profile

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.